Nymox Pharmaceutical Stock Price, News & Analysis (NASDAQ:NYMX)

$3.13 -0.06 (-1.88 %)
(As of 02/22/2018 05:42 AM ET)
Previous Close$3.19
Today's Range$3.12 - $3.30
52-Week Range$3.00 - $5.10
Volume151,700 shs
Average Volume214,654 shs
Market Capitalization$174.91 million
P/E Ratio10.10
Dividend YieldN/A
Beta0.84

About Nymox Pharmaceutical (NASDAQ:NYMX)

Nymox Pharmaceutical logoNymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The Company also has a patent portfolio covering its marketed products, its investigational drug, as well as other therapeutic and diagnostic indications. The Company also has the United States and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company's subsidiaries include Nymox Corporation and Serex, Inc. Nymox Corporation conducts research and development, while Serex conducts research and development, and manufacturing for NicAlert and TobacAlert.

Receive NYMX News and Ratings via Email

Sign-up to receive the latest news and ratings for NYMX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic Substances
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NYMX
CUSIPN/A
Phone800-936-9669

Debt

Debt-to-Equity Ratio61.64%
Current Ratio1.44%
Quick Ratio1.42%

Price-To-Earnings

Trailing P/E Ratio10.0967741935484
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$280,000.00
Price / Sales612.92
Cash FlowN/A
Price / CashN/A
Book Value($0.01) per share
Price / Book-313.00

Profitability

Trailing EPS$0.31
Net Income$-13,100,000.00
Net Margins-8,237.58%
Return on EquityN/A
Return on Assets-753.01%

Miscellaneous

Employees6
Outstanding Shares54,830,000

Nymox Pharmaceutical (NASDAQ:NYMX) Frequently Asked Questions

What is Nymox Pharmaceutical's stock symbol?

Nymox Pharmaceutical trades on the NASDAQ under the ticker symbol "NYMX."

How were Nymox Pharmaceutical's earnings last quarter?

Nymox Pharmaceutical Co. (NASDAQ:NYMX) posted its quarterly earnings data on Friday, November, 14th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter. The biopharmaceutical company had revenue of $0.08 million for the quarter. View Nymox Pharmaceutical's Earnings History.

When will Nymox Pharmaceutical make its next earnings announcement?

Nymox Pharmaceutical is scheduled to release their next quarterly earnings announcement on Friday, March, 30th 2018. View Earnings Estimates for Nymox Pharmaceutical.

Who are some of Nymox Pharmaceutical's key competitors?

Who owns Nymox Pharmaceutical stock?

Nymox Pharmaceutical's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.34%), Wedbush Securities Inc. (0.51%) and Deutsche Bank AG (0.13%). View Institutional Ownership Trends for Nymox Pharmaceutical.

Who bought Nymox Pharmaceutical stock? Who is buying Nymox Pharmaceutical stock?

Nymox Pharmaceutical's stock was bought by a variety of institutional investors in the last quarter, including Deutsche Bank AG, BlackRock Inc. and Wedbush Securities Inc.. View Insider Buying and Selling for Nymox Pharmaceutical.

How do I buy Nymox Pharmaceutical stock?

Shares of Nymox Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nymox Pharmaceutical's stock price today?

One share of Nymox Pharmaceutical stock can currently be purchased for approximately $3.13.

How big of a company is Nymox Pharmaceutical?

Nymox Pharmaceutical has a market capitalization of $174.91 million and generates $280,000.00 in revenue each year. The biopharmaceutical company earns $-13,100,000.00 in net income (profit) each year or $0.31 on an earnings per share basis. Nymox Pharmaceutical employs 6 workers across the globe.

How can I contact Nymox Pharmaceutical?

Nymox Pharmaceutical's mailing address is 9900 CAVENDISH BLVD. SUITE 306, St.-Laurent A8, H4M 2V2. The biopharmaceutical company can be reached via phone at 800-936-9669 or via email at [email protected]


MarketBeat Community Rating for Nymox Pharmaceutical (NYMX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  58 (Vote Outperform)
Underperform Votes:  56 (Vote Underperform)
Total Votes:  114
MarketBeat's community ratings are surveys of what our community members think about Nymox Pharmaceutical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Nymox Pharmaceutical (NASDAQ:NYMX) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Nymox Pharmaceutical (NASDAQ:NYMX) Earnings History and Estimates Chart

Earnings by Quarter for Nymox Pharmaceutical (NASDAQ:NYMX)

Nymox Pharmaceutical (NASDAQ NYMX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/30/2018        
8/7/2017Q2 2017($0.05)$0.01 millionViewN/AView Earnings Details
5/15/2017Q1 2017($0.06)$0.08 millionViewN/AView Earnings Details
3/31/2017Q4 2016($0.06)$0.04 millionViewN/AView Earnings Details
11/15/2016Q3 2016($0.07)$0.05 millionViewN/AView Earnings Details
8/22/2016Q2 2016($0.08)$0.15 millionViewN/AView Earnings Details
5/16/2016Q1 2016($0.07)$0.04 millionViewN/AView Earnings Details
3/30/2016Q4 2015($0.10)$0.08 millionViewN/AView Earnings Details
12/31/2015Q3 2015($0.26)$0.05 millionViewN/AView Earnings Details
8/24/2015Q2 2015($0.63)$0.06 millionViewN/AView Earnings Details
5/15/2015Q1 2015$0.04$0.08 millionViewN/AView Earnings Details
3/31/2015Q4 2014($0.01)$0.08 millionViewN/AView Earnings Details
11/14/2014Q314($0.02)$0.08 millionViewN/AView Earnings Details
8/11/2014Q2 2014($0.02)$0.10 millionViewN/AView Earnings Details
5/15/2014Q1 2014($0.07)$0.08 millionViewN/AView Earnings Details
3/14/2014Q4 2013($0.03)$0.94 millionViewN/AView Earnings Details
11/13/2013Q3($0.03)$0.74 millionViewN/AView Earnings Details
8/14/2013Q2 2013($0.04)$0.19 millionViewN/AView Earnings Details
5/15/2013Q1 2013($0.05)($0.03)$0.78 million$0.18 millionViewN/AView Earnings Details
3/15/2013Q4 2012($0.05)($0.08)ViewN/AView Earnings Details
11/14/2012Q312($0.06)($0.04)ViewN/AView Earnings Details
8/14/2012Q2 2012($0.06)($0.05)ViewN/AView Earnings Details
5/15/2012Q1 2012($0.06)($0.06)ViewN/AView Earnings Details
3/15/2012Q4 2011($0.06)($0.06)ViewN/AView Earnings Details
11/14/2011Q3 2011($0.05)($0.05)ViewN/AView Earnings Details
8/12/2011Q2 2011($0.04)($0.06)ViewN/AView Earnings Details
5/13/2011Q1 2011($0.05)($0.14)ViewN/AView Earnings Details
3/15/2011Q4 2010($0.05)($0.07)ViewN/AView Earnings Details
11/12/2010Q3 2010($0.05)ViewN/AView Earnings Details
8/13/2010Q2 2010($0.05)ViewN/AView Earnings Details
5/14/2010Q1 2010($0.04)ViewN/AView Earnings Details
3/11/2010Q4 2009($0.05)ViewN/AView Earnings Details
11/13/2009Q3 2009($0.04)ViewN/AView Earnings Details
8/14/2009Q2 2009($0.04)ViewN/AView Earnings Details
5/15/2009Q1 2009($0.03)ViewN/AView Earnings Details
11/14/2008Q3 2008($0.05)ViewN/AView Earnings Details
8/13/2008Q2 2008($0.04)ViewN/AView Earnings Details
5/14/2008Q1 2008($0.04)ViewN/AView Earnings Details
3/14/2008Q4 2007($0.04)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Nymox Pharmaceutical (NASDAQ:NYMX) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Nymox Pharmaceutical (NASDAQ:NYMX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Nymox Pharmaceutical (NASDAQ NYMX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 54.00%
Institutional Ownership Percentage: 6.05%
Insider Trades by Quarter for Nymox Pharmaceutical (NASDAQ:NYMX)
Institutional Ownership by Quarter for Nymox Pharmaceutical (NASDAQ:NYMX)

Nymox Pharmaceutical (NASDAQ NYMX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/16/2018James George RobinsonDirectorBuy7,000$3.27$22,890.00View SEC Filing  
2/12/2018James George RobinsonDirectorBuy8,000$3.27$26,160.003,107,850View SEC Filing  
2/8/2018James George RobinsonDirectorBuy10,000$3.37$33,700.003,091,050View SEC Filing  
2/2/2018James George RobinsonDirectorBuy5,000$3.47$17,350.003,090,550View SEC Filing  
1/18/2018James George RobinsonDirectorBuy3,000$3.14$9,420.003,085,550View SEC Filing  
8/3/2017James George RobinsonDirectorBuy10,000$3.73$37,300.003,077,550View SEC Filing  
8/2/2017James George RobinsonDirectorBuy5,000$3.79$18,950.003,077,550View SEC Filing  
8/1/2017James George RobinsonDirectorBuy15,000$3.72$55,800.003,062,550View SEC Filing  
7/7/2017James George RobinsonDirectorBuy11,500$4.00$46,000.003,046,550View SEC Filing  
7/6/2017James George RobinsonDirectorBuy3,000$3.92$11,760.003,046,550View SEC Filing  
7/5/2017James George RobinsonDirectorBuy5,000$3.97$19,850.003,046,550View SEC Filing  
6/28/2017James George RobinsonDirectorBuy8,500$4.09$34,765.003,040,050View SEC Filing  
6/26/2017James George RobinsonDirectorBuy15,000$3.80$57,000.003,027,550View SEC Filing  
6/21/2017James George RobinsonDirectorBuy15,000$3.77$56,550.003,008,150View SEC Filing  
6/20/2017James George RobinsonDirectorBuy5,000$3.76$18,800.003,008,150View SEC Filing  
6/19/2017James George RobinsonDirectorBuy5,000$3.79$18,950.003,008,150View SEC Filing  
5/30/2017James George RobinsonDirectorBuy54,500$3.81$207,645.002,957,550View SEC Filing  
3/8/2017James George RobinsonDirectorBuy50,000$3.59$179,500.002,906,078View SEC Filing  
8/10/2016James George RobinsonDirectorBuy500$2.47$1,235.002,907,550View SEC Filing  
8/4/2016James George RobinsonDirectorBuy7,000$3.41$23,870.002,902,550View SEC Filing  
7/29/2016James George RobinsonDirectorBuy22,500$3.86$86,850.002,880,050View SEC Filing  
7/20/2016James George RobinsonDirectorBuy10,000$3.33$33,300.002,870,050View SEC Filing  
7/7/2016James George RobinsonDirectorBuy20,000$3.28$65,600.002,850,050View SEC Filing  
6/29/2016James George RobinsonDirectorBuy17,500$3.53$61,775.002,833,050View SEC Filing  
6/24/2016James George RobinsonDirectorBuy22,500$2.97$66,825.002,810,050View SEC Filing  
5/13/2016James George RobinsonDirectorBuy28,010$2.31$64,703.102,782,550View SEC Filing  
5/3/2016James George RobinsonDirectorBuy6,990$2.36$16,496.402,777,050View SEC Filing  
4/29/2016James George RobinsonDirectorBuy15,000$2.27$34,050.002,762,550View SEC Filing  
4/15/2016James George RobinsonDirectorBuy39,500$2.39$94,405.002,722,550View SEC Filing  
4/1/2016James George RobinsonDirectorBuy20,500$2.40$49,200.002,701,050View SEC Filing  
3/24/2016James George RobinsonDirectorBuy40,000$2.29$91,600.002,659,050View SEC Filing  
1/12/2016James George RobinsonDirectorBuy20,000$2.44$48,800.002,657,550View SEC Filing  
1/8/2016James George RobinsonDirectorBuy95,000$2.90$275,500.002,637,550View SEC Filing  
12/30/2015James George RobinsonDirectorBuy5,000$3.38$16,900.002,542,550View SEC Filing  
12/29/2015James George RobinsonDirectorBuy14,000$3.55$49,700.002,542,550View SEC Filing  
12/28/2015James George RobinsonDirectorBuy6,000$3.79$22,740.002,542,550View SEC Filing  
12/23/2015James George RobinsonDirectorBuy29,854$3.54$105,683.162,517,550View SEC Filing  
12/18/2015James George RobinsonDirectorBuy63,334$3.56$225,469.042,487,696View SEC Filing  
12/11/2015James George RobinsonDirectorBuy46,812$3.51$164,310.122,424,362View SEC Filing  
12/4/2015James George RobinsonDirectorBuy110,000$3.44$378,400.002,377,550View SEC Filing  
9/3/2015James George RobinsonDirectorBuy100,000$2.25$225,000.002,267,550View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Nymox Pharmaceutical (NASDAQ NYMX) News Headlines

Source:
DateHeadline
Nymox Pharmaceutical Co. (NYMX) Director James George Robinson Buys 7,000 SharesNymox Pharmaceutical Co. (NYMX) Director James George Robinson Buys 7,000 Shares
www.americanbankingnews.com - February 20 at 7:50 PM
James George Robinson Purchases 8,000 Shares of Nymox Pharmaceutical Co. (NYMX) StockJames George Robinson Purchases 8,000 Shares of Nymox Pharmaceutical Co. (NYMX) Stock
www.americanbankingnews.com - February 13 at 12:30 PM
Nymox Pharmaceutical Co. (NYMX) Director James George Robinson Buys 10,000 SharesNymox Pharmaceutical Co. (NYMX) Director James George Robinson Buys 10,000 Shares
www.americanbankingnews.com - February 9 at 6:34 PM
Nymox Pharmaceutical Co. (NYMX) Director Acquires $17,350.00 in StockNymox Pharmaceutical Co. (NYMX) Director Acquires $17,350.00 in Stock
www.americanbankingnews.com - February 6 at 7:00 PM
Nymox Announces US NDA for Fexapotide for BPH - GlobeNewswire (press release)Nymox Announces US NDA for Fexapotide for BPH - GlobeNewswire (press release)
globenewswire.com - February 6 at 9:06 AM
Nymox Announces US NDA for Fexapotide for BPHNymox Announces US NDA for Fexapotide for BPH
finance.yahoo.com - February 5 at 4:25 PM
The Clock Is Ticking For Nymox Pharmas European Drug Application - Bet On A Rejection - Seeking AlphaThe Clock Is Ticking For Nymox Pharma's European Drug Application - Bet On A Rejection - Seeking Alpha
seekingalpha.com - February 2 at 9:08 AM
Fexapotide BPH Phase 3 Clinical Trial Results Published in World Journal of UrologyFexapotide BPH Phase 3 Clinical Trial Results Published in World Journal of Urology
finance.yahoo.com - January 30 at 9:33 AM
Nymox Pharma (NYMX) Announces 5-Year Results From Prospective Randomized Controlled Prostate Cancer Study of Fexapotide Triflutate in 146 U.S. MenNymox Pharma (NYMX) Announces 5-Year Results From Prospective Randomized Controlled Prostate Cancer Study of Fexapotide Triflutate in 146 U.S. Men
www.streetinsider.com - January 23 at 4:06 PM
Nymox Pharma (NYMX) Announces 5-Year Results From Prospective Randomized Controlled Prostate Cancer Study ... - StreetInsider.comNymox Pharma (NYMX) Announces 5-Year Results From Prospective Randomized Controlled Prostate Cancer Study ... - StreetInsider.com
www.streetinsider.com - January 23 at 8:19 AM
AMGNs LIBERTY Meets Goals, ANTH Yields RESULT, CCXI Up On Cancer Trial Data - NasdaqAMGN's LIBERTY Meets Goals, ANTH Yields RESULT, CCXI Up On Cancer Trial Data - Nasdaq
www.nasdaq.com - January 23 at 8:19 AM
Nymox Reports 5-Year Results From Prospective Randomized Controlled Prostate Cancer Study of Fexapotide Triflutate in 146 U.S. MenNymox Reports 5-Year Results From Prospective Randomized Controlled Prostate Cancer Study of Fexapotide Triflutate in 146 U.S. Men
finance.yahoo.com - January 22 at 5:50 PM
ETFs with exposure to Nymox Pharmaceutical Corp. : December 22, 2017ETFs with exposure to Nymox Pharmaceutical Corp. : December 22, 2017
finance.yahoo.com - December 22 at 7:31 PM
ETFs with exposure to Nymox Pharmaceutical Corp. : December 11, 2017ETFs with exposure to Nymox Pharmaceutical Corp. : December 11, 2017
finance.yahoo.com - December 11 at 4:44 PM
ETFs with exposure to Nymox Pharmaceutical Corp. : November 30, 2017ETFs with exposure to Nymox Pharmaceutical Corp. : November 30, 2017
finance.yahoo.com - November 30 at 4:34 PM
Nymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017Nymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 10:25 AM
Nymox Fexapotide Symposium and Panel Discussion at American ... - GlobeNewswire (press release)Nymox Fexapotide Symposium and Panel Discussion at American ... - GlobeNewswire (press release)
globenewswire.com - November 27 at 4:43 PM
Symposium and Panel Discussion on Nymoxs Fexapotide To Be Held at American Urological AssociationSymposium and Panel Discussion on Nymox's Fexapotide To Be Held at American Urological Association
www.nasdaq.com - November 12 at 11:14 AM
Symposium and Panel Discussion on Nymoxs Fexapotide To Be Held at American Urological Association North ...Symposium and Panel Discussion on Nymox's Fexapotide To Be Held at American Urological Association North ...
globenewswire.com - November 12 at 11:14 AM
Nymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological ... - NasdaqNymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological ... - Nasdaq
www.nasdaq.com - November 9 at 7:56 AM
Nymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological Association ...Nymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological Association ...
globenewswire.com - November 7 at 4:34 PM
Nymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological Association New York Section Annual Meeting in HavanaNymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological Association New York Section Annual Meeting in Havana
finance.yahoo.com - November 7 at 4:34 PM
Notable Wednesday Option Activity: ULTI, NYMX, XPO - NasdaqNotable Wednesday Option Activity: ULTI, NYMX, XPO - Nasdaq
www.nasdaq.com - November 2 at 7:11 AM
Nymox Pharmaceutical Corporation (NYMX) Short Interest Down 22.8% in OctoberNymox Pharmaceutical Corporation (NYMX) Short Interest Down 22.8% in October
www.americanbankingnews.com - October 28 at 2:26 AM
Short Interest Drops 22.8% For NYMXShort Interest Drops 22.8% For NYMX
www.thestreet.com - October 27 at 8:53 AM
Nymox Pharmaceutical Corporation (NYMX): How Does It Impact Your Portfolio?Nymox Pharmaceutical Corporation (NYMX): How Does It Impact Your Portfolio?
finance.yahoo.com - October 27 at 8:53 AM
Nymox Reports on Symposium, Panel Discussion with Abstract on Fexapotide at American Urological Association Northeast ...Nymox Reports on Symposium, Panel Discussion with Abstract on Fexapotide at American Urological Association Northeast ...
globenewswire.com - October 14 at 6:23 AM
Nymox Reports on Symposium, Panel Discussion with Abstract on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in SavannahNymox Reports on Symposium, Panel Discussion with Abstract on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in Savannah
finance.yahoo.com - October 14 at 6:23 AM
Nymox Pharmaceutical Corporation (NYMX) Sees Significant Decrease in Short InterestNymox Pharmaceutical Corporation (NYMX) Sees Significant Decrease in Short Interest
www.americanbankingnews.com - October 14 at 1:40 AM
Short Interest Falls 63.6% For NYMXShort Interest Falls 63.6% For NYMX
www.thestreet.com - October 12 at 7:45 AM
Nymox Reports on Symposium and Panel Discussion on Fexapotide at American Urological Association Northeast Sectional ...Nymox Reports on Symposium and Panel Discussion on Fexapotide at American Urological Association Northeast Sectional ...
globenewswire.com - October 11 at 5:52 AM
Nymox Announces October 12 Symposium for Companys BPH Drug at American Urological Association MeetingNymox Announces October 12 Symposium for Company's BPH Drug at American Urological Association Meeting
finance.yahoo.com - October 2 at 7:25 PM
Nymox Pharma (NYMX) Says Its MAA For Fexapotide Triflutate was Validated - StreetInsider.comNymox Pharma (NYMX) Says Its MAA For Fexapotide Triflutate was Validated - StreetInsider.com
www.streetinsider.com - September 15 at 7:03 AM
Nymox Announces New Symposium for Companys BPH Drug at American Urological Association Meeting October 5Nymox Announces New Symposium for Company's BPH Drug at American Urological Association Meeting October 5
finance.yahoo.com - September 15 at 7:03 AM
Nymox Application Validated:Nymox Application Validated:
finance.yahoo.com - September 15 at 7:03 AM
AUA Meeting in Florida September 16 Postponed Due to HurricaneAUA Meeting in Florida September 16 Postponed Due to Hurricane
finance.yahoo.com - September 12 at 7:40 AM
ETFs with exposure to Nymox Pharmaceutical Corp. : September 12, 2017ETFs with exposure to Nymox Pharmaceutical Corp. : September 12, 2017
finance.yahoo.com - September 12 at 7:40 AM
ETFs with exposure to Nymox Pharmaceutical Corp. : August 31, 2017ETFs with exposure to Nymox Pharmaceutical Corp. : August 31, 2017
finance.yahoo.com - September 1 at 6:37 AM
Nymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017Nymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 25 at 9:32 AM
Nymox Announces Private Placements of $3 MillionNymox Announces Private Placements of $3 Million
finance.yahoo.com - August 10 at 6:23 AM
Nymox Announces Symposium for Companys BPH Drug at ... - NasdaqNymox Announces Symposium for Company's BPH Drug at ... - Nasdaq
www.nasdaq.com - August 8 at 2:39 AM
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Director James George Robinson Acquires 10,000 SharesNymox Pharmaceutical Corporation (NASDAQ:NYMX) Director James George Robinson Acquires 10,000 Shares
www.americanbankingnews.com - August 4 at 9:00 PM
Insider Buying: Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Director Buys 5,000 Shares of StockInsider Buying: Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Director Buys 5,000 Shares of Stock
www.americanbankingnews.com - August 4 at 9:00 PM
ETFs with exposure to Nymox Pharmaceutical Corp. : August 4, 2017ETFs with exposure to Nymox Pharmaceutical Corp. : August 4, 2017
finance.yahoo.com - August 4 at 6:32 AM
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Director James George Robinson Acquires 15,000 SharesNymox Pharmaceutical Corporation (NASDAQ:NYMX) Director James George Robinson Acquires 15,000 Shares
www.americanbankingnews.com - August 1 at 8:21 PM
Nymox Pharmaceutical Corporation (NYMX) Director James George Robinson Buys 11,500 SharesNymox Pharmaceutical Corporation (NYMX) Director James George Robinson Buys 11,500 Shares
www.americanbankingnews.com - July 7 at 9:03 PM
Nymox Pharmaceutical Corporation (NYMX) Director James George Robinson Acquires 5,000 SharesNymox Pharmaceutical Corporation (NYMX) Director James George Robinson Acquires 5,000 Shares
www.americanbankingnews.com - July 7 at 9:02 PM
Insider Buying: Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Director Acquires 3,000 Shares of StockInsider Buying: Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Director Acquires 3,000 Shares of Stock
www.americanbankingnews.com - July 7 at 9:02 PM
Commit To Purchase Nymox Pharmaceutical Corp At $3, Earn 25% Using OptionsCommit To Purchase Nymox Pharmaceutical Corp At $3, Earn 25% Using Options
www.thestreet.com - July 6 at 7:37 AM
ETFs with exposure to Nymox Pharmaceutical Corp. : July 4, 2017ETFs with exposure to Nymox Pharmaceutical Corp. : July 4, 2017
finance.yahoo.com - July 5 at 9:08 AM

SEC Filings

Nymox Pharmaceutical (NASDAQ:NYMX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Nymox Pharmaceutical (NASDAQ:NYMX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Nymox Pharmaceutical (NASDAQ NYMX) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.